Published Studies Related to Alphagan P (Brimonidine Ophthalmic)
Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. [2011.06]
PURPOSE: To assess the impact of open versus masked adherence monitoring on adherence with topical brimonidine using two different dosing schedules... CONCLUSION: The study findings suggest that adherence measurements are not significantly altered by open adherence monitoring, which may simplify future adherence studies. Adherence with brimonidine eye drops was insufficient for most patients. These results demonstrate the necessity to develop new strategies to improve compliance in glaucoma therapy. (c) 2010 The Authors. Acta Ophthalmologica (c) 2010 Acta Ophthalmologica Scandinavica Foundation.
A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. [2011.04]
PURPOSE: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma. DESIGN: Randomized, double-masked, multicenter clinical trial... CONCLUSION: Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification. [2011.02]
PURPOSE: To evaluate the effect of a fixed combination of brimonidine-timolol on intraocular pressure (IOP) after phacoemulsification cataract surgery. SETTING: Department of Ophthalmology, Patras University Hospital, Patras, Greece. DESIGN: Prospective randomized comparative case series... CONCLUSION: The fixed brimonidine-timolol combination effectively reduced IOP 6, 12, and 24 hours after phacoemulsification cataract surgery. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. [2011.02]
PURPOSE: Brimonidine (0.15%), which is used to lower intraocular pressure, is an alpha-2-adrenergic agonist that has vasoconstrictive effects. This study examined whether the administration of brimonidine (0.15%) before intravitreal injection prevents subconjunctival hemorrhage... CONCLUSION: The administration of 0.15% brimonidine before an intravitreal injection decreased the incidence, severity, and size of subconjunctival hemorrhage.
Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. [2011.01]
PURPOSE: To evaluate control of intraocular pressure (IOP) and IOP fluctuation in patients with ocular hypertension or glaucoma treated with fixed-combination brimonidine-timolol compared with brimonidine or timolol monotherapy. DESIGN: Post hoc analysis of data from 2 identical, 12-month, randomized, double-masked, multicenter trials... CONCLUSIONS: Patients treated with fixed-combination brimonidine-timolol were more likely than patients treated with either brimonidine or timolol alone to achieve a combination of low mean IOP and low short-term (daily) or long-term (intervisit) IOP fluctuation. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Alphagan P (Brimonidine Ophthalmic)
Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature [Recruiting]
It is already known that the local treatment with Alphagan eye drops (a drug commonly used
by glaucoma patients) reduces ocular blood flow. In-vitro studies suggest that the
vasoconstrictive effect of Alphagan is more pronounced when this drug is combined with a
prostaglandin analogue (eg. Xalatan eye drops). The investigators also question whether
this effect is more pronounced in subjects suffering from a primary vascular dysregulation
(PVD). To test for the effect of these drugs on PVD and non-PVD subjects the investigators
will take measurements of corneal temperature as surrogate for ocular blood flow.
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Completed]
This study evaluates the safety and efficacy of brimonidine 0. 2%/timolol 0. 5% fixed
combination ophthalmic solution compared with concurrent brimonidine 0. 2% and timolol
Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma [Recruiting]
The investigators have completed a study in which the investigators examined the response of
the retinal circulation to changes in posture from sitting to lying down in patients with
Normal Tension Glaucoma (NTG). This alteration in position produces changes in the local
blood pressure at the entrance to the retinal vasculature. In a healthy retina, the
vasculature adapts by dilating and constricting in order to maintain a steady blood flow
rate. In an eye with NTG, this often does not occur. Upon analysis at the completion of
the study , the investigators found that the patients who had been taking Alphagan
(brimonidine) during the study did not exhibit the blood flow increases typical of NTG while
lying down; instead, they maintained a steady blood flow rate as did the group of healthy
control subjects. The investigators primary objective is to now demonstrate in a
prospective study that Alphagan can restore retinal vascular autoregulatory function in
patients with NTG who do not autoregulate. The investigators will also determine the effect
of Alphagan treatment on the patients' ability to detect motion.
Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Recruiting]
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed
combination compared with brimonidine tartrate and timolol in patients with glaucoma or
ocular hypertension who do not respond well to topical beta blockers.
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% [Recruiting]
Reports of Suspected Alphagan P (Brimonidine Ophthalmic) Side Effects
Ocular Hyperaemia (5),
Visual Field Defect (3),
Confusional State (2),
Optic Nerve Disorder (2),
Intraocular Pressure Increased (2),
Drug Interaction (2),
Impaired Driving Ability (2),
Malaise (2), more >>